Literature DB >> 24840608

Impact of small study bias on cost-effectiveness acceptability curves and value of information analyses.

Dirk Müller1, Eleanor Pullenayegum, Afschin Gandjour.   

Abstract

It is well known that small, randomized, controlled trials (RCTs) have limited validity. When comparing the results of meta-analyses with those of later large trials or with those of large trials removed from the meta-analyses, discrepancies were reported. This paper addresses two issues: (1) how measures of the uncertainty in cost-effectiveness, i.e., cost-effectiveness acceptability curves (CEACs), and the expected value of perfect information (EVPI) are affected by the limited validity of small trials and (2) how to deal with this bias. To this end, the paper adopts a Bayesian approach. Using empirical estimates for the validity of small RCTs compared to larger RCTs, the probability of cost-effectiveness drops by almost 10 %, while the EVPI is three times higher. In conclusion, traditional CEACs and EVPI analyses based on (small) RCTs may need careful appraisal. Ignoring prior evidence on the validity of small-size trials leads to an underestimation of uncertainty in cost-effectiveness. For future economic analyses, it is important to incorporate aspects of uncertainty which are caused by flawed data on effectiveness .

Entities:  

Mesh:

Year:  2014        PMID: 24840608     DOI: 10.1007/s10198-014-0607-3

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  39 in total

Review 1.  Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis.

Authors:  J A Sterne; M Egger; G D Smith
Journal:  BMJ       Date:  2001-07-14

2.  The value of implementation and the value of information: combined and uneven development.

Authors:  Elisabeth Fenwick; Karl Claxton; Mark Sculpher
Journal:  Med Decis Making       Date:  2008 Jan-Feb       Impact factor: 2.583

3.  Cost-effectiveness and value of information analyses of neuraminidase inhibitors for the treatment of influenza.

Authors:  Allan J Wailoo; Alexander J Sutton; Nicola J Cooper; David A Turner; Keith R Abrams; Alan Brennan; Karl G Nicholson
Journal:  Value Health       Date:  2008 Mar-Apr       Impact factor: 5.725

4.  Predictive ability of meta-analyses of randomised controlled trials.

Authors:  J Villar; G Carroli; J M Belizán
Journal:  Lancet       Date:  1995-03-25       Impact factor: 79.321

5.  Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis.

Authors:  Bas Groot Koerkamp; M G Myriam Hunink; Theo Stijnen; James K Hammitt; Karen M Kuntz; Milton C Weinstein
Journal:  Med Decis Making       Date:  2007 Mar-Apr       Impact factor: 2.583

Review 6.  Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis.

Authors:  Alexander C Ford; Brendan C Delaney; David Forman; Paul Moayyedi
Journal:  Am J Gastroenterol       Date:  2004-09       Impact factor: 10.864

7.  More is not always better: cost-effectiveness analysis of combined, single behavioral and single physical rehabilitation programs for chronic low back pain.

Authors:  Rob J Smeets; Johan L Severens; Saskia Beelen; Johan W Vlaeyen; J André Knottnerus
Journal:  Eur J Pain       Date:  2008-04-22       Impact factor: 3.931

8.  Economic evaluation comparing From Home To Operation same day admission and preoperative admission one day prior to the surgery process: a randomized, controlled trial of laparoscopic cholecystectomy.

Authors:  J Keränen; E J O Soini; O-P Ryynänen; K Hietaniemi; U Keränen
Journal:  Curr Med Res Opin       Date:  2007-11       Impact factor: 2.580

9.  The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis--a simulation study.

Authors:  Kristian Thorlund; Georgina Imberger; Michael Walsh; Rong Chu; Christian Gluud; Jørn Wetterslev; Gordon Guyatt; Philip J Devereaux; Lehana Thabane
Journal:  PLoS One       Date:  2011-10-18       Impact factor: 3.240

10.  The fading of reported effectiveness. A meta-analysis of randomised controlled trials.

Authors:  Bernhard T Gehr; Christel Weiss; Franz Porzsolt
Journal:  BMC Med Res Methodol       Date:  2006-05-11       Impact factor: 4.615

View more
  1 in total

1.  Applying GRADE Criteria to Clinical Inputs to Cost-Effectiveness Modeling Studies.

Authors:  Alexander Mensch; Tanja Beck; Daniele Civello; Christopher Kunigkeit; Nicole Lachmann; Stephanie Stock; Afschin Gandjour; Dirk Müller
Journal:  Pharmacoeconomics       Date:  2018-08       Impact factor: 4.981

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.